Assessment of Effect of Rapastinel on Driving Performance
Status:
Completed
Trial end date:
2019-04-03
Target enrollment:
Participant gender:
Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate
the participant's driving performance after single IV doses of rapastinel as compared with
single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and
placebo in healthy participants.